Minimal Invasive Surgical Techniques (MIST): wie relevant ist der ganze Mist?

Zusammenfassung

Aufgrund der steigenden Lebenserwartung und der wachsenden Nachfrage nach BPH-Behandlungen wurden innovative Technologien entwickelt, die eine zügige Erholung, Symptomlinderung, geringe Komplikationsraten sowie die Durchführung des Eingriffs ambulant und teilweise unter lokaler Betäubung ermöglichen. Das Ziel dieser Übersichtsarbeit ist es, die Ergebnisse der funktionellen Miktionsparameter und der sexuellen Funktion neu entwickelter minimalinvasiver chirurgischer Therapien (MIST) zur Behandlung der BPH zu beschreiben. Diese werden in primär ablative (Aquaablation [Aquabeam]), nicht-ablative (Prostata-Harnröhren-Lifting-Verfahren [PUL, Urolift], temporär implantierbare Körbchen [iTind]), und sekundär ablative Verfahren (konvektive Wasserdampfablation, Rezum, Prostataarterienembolisation [PAE]) unterschieden. Alle MIST-Technologien haben die medizinische Versorgung der BPH mit der Erhaltung der Ejakulation vorangetrieben. Langzeitdaten, die sich speziell mit Reinterventionsraten und den Erhalt der funktionellen Miktionsparameter beschäftigen, sind derzeit jedoch noch eine Seltenheit. Trotz vielversprechender Daten aus den Zulassungsstudien sowie aus randomisierten Studien, zeigen alle MIST-Therapien auch schwerwiegende Komplikationen. Patienten, die für eine solche Methode vorstellig werden, müssen über die Unterlegenheit im Gegensatz zu den etablierten transurethralen Verfahren wie die TUR-P und die Enukleation umfassend aufgeklärt werden.

Abstract

As life expectancy increases and there is growing demand for BPH treatments, innovative technologies have been developed, allowing for swift recovery, symptom relief, low complication rates, and the possibility of performing procedures on an outpatient basis, often under local anaesthesia. This review aims to describe the outcomes of newly developed minimally-invasive surgical therapies (MIST) for BPH treatment in terms of functional voiding parameters and sexual function. These therapies are categorized into primarily ablative (Aquablation [Aquabeam]), non-ablative (Prostatic Urethral Lift (PUL, Urolift), temporary implantable devices [iTind]), and secondarily ablative procedures (convective water vapor ablation, Rezum, Prostate Artery Embolization [PAE]). All MIST technologies have advanced the medical care of patients with BPH while preserving ejaculation. However, there is a shortage of long-term data specifically addressing re-intervention rates and the preservation of functional voiding parameters. Although there is promising data from regulatory trials and randomized studies, all MIST therapies are potentially associated with severe complications. Patients considering such methods must be thoroughly informed about their inferiority compared with established transurethral procedures like TUR-P and enucleation.

Schlüsselwörter

PUL - Aquaablation - PAE - iTind - Rezum

Keywords

PUL - Aquablation - PAE - iTind - Rezum

Publication History

Received: 27 January 2024

Accepted: 12 February 2024

Article published online:
28 March 2024

• Literatur

• 1 Cornu JN, Gacci M, Hashim H. et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) EAU. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2023.pdf
• 2 Magistro G, Abt SD, Becher KF. et al. Surgical treatment options of lower urinary tract symptoms due to benign prostatic obstruction: The German S2e guideline 2023-part 3. Urologie 2023; 62: 1177-1185 DOI: 10.1007/s00120-023-02200-7. (PMID: 37823934)
• 3 Salem J, Becher KF, Bschleipfer T. et al. [Minimally invasive treatment of benign prostatic hyperplasia: The German S2e guideline 2023-part 4]. Urologie 2024; DOI: 10.1007/s00120-023-02249-4. (PMID: 38193989)
• 4 Porpiglia F, Fiori C, Bertolo R. et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 2015; 116: 278-287
• 5 Porpiglia F, Fiori C, Bertolo R. et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 2018; 122: 106-112 DOI: 10.1111/bju.14141. (PMID: 29359881)
• 6 Porpiglia F, Fiori C, Amparore D. et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int 2019; 123: 1061-1069 DOI: 10.1111/bju.14608. (PMID: 30382600)
• 7 Chughtai B, Elterman D, Shore N. et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology 2021; 153: 270-276 DOI: 10.1016/j.urology.2020.12.022. (PMID: 33373708)
• 8 Elterman D, Alshak MN, Martinez Diaz S. et al. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol 2023; 37: 74-79
• 9 De Nunzio C, Cantiello F, Fiori C. et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol 2021; 39: 2037-2042
• 10 Kadner G, Valerio M, Giannakis I. et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol 2020; 38: 3235-3244
• 11 Amparore D, Fiori C, Valerio M. et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis 2021; 24: 349-357
• 12 Amparore D, De Cillis S, Schulman C. et al. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol 2023; 75: 743-751 DOI: 10.23736/S2724-6051.23.05322-3. (PMID: 37350585)
• 13 Woo HH, Chin PT, McNicholas TA. et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011; 108: 82-88 DOI: 10.1111/j.1464-410X.2011.10342.x. (PMID: 21554526)
• 14 Rukstalis D, Grier D, Stroup SP. et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the Medlift study. ProstateCancerProstaticDis 2019; 22: 411-419 DOI: 10.1038/s41391-018-0118-x. (PMID: 30542055)
• 15 Rabinowitz MJ, Alam R, Liu JL. et al. Prostatic Urethral Lift in Patients With Obstructive Median Lobes: A Single Surgeon Experience at an Academic Center. Urology 2021; 154: 237-242
• 16 Eure G, Rukstalis D, Roehrborn C. Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings. J Endourol 2023; 37: 50-59 DOI: 10.1089/end.2022.0324. (PMID: 35876440)
• 17 Ashley MS, Phillips J, Eure G. How I Do It: The prostatic urethral lift for obstructive median lobes. Can J Urol 2023; 30: 11509-11515 (PMID: 37074752)
• 18 Perera M, Roberts MJ, Doi SA. et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 2015; 67: 704-713
• 19 Roehrborn CG, Gange SN, Shore ND. et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the LIFT study. J Urol 2013; 190: 2161-2167
• 20 Roehrborn CG, Rukstalis DB, Barkin J. et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 2015; 22: 7772-7782 (PMID: 26068624)
• 21 Roehrborn CG, Barkin J, Gange SN. et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24: 8802-8813 (PMID: 28646935)
• 22 Sønksen J, Barber NJ, Speakman MJ. et al. Prospective, randomized, multinational study of prostatic urethral lift ver- sus transurethral resection of the prostate: 12- month results from the BPH6 study. Eur Urol 2015; 68: 643-652
• 23 Gratzke C, Barber N, Speakman MJ. et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017; 119: 767-775 DOI: 10.1111/bju.13714. (PMID: 27862831)
• 24 Page T, Veeratterapillay R, Keltie K. et al. Prostatic urethral lift (UroLift): a real-world analysis of outcomes using hospital episodes statistics. BMC Urol 2021; 21: 55 DOI: 10.1186/s12894-021-00824-5. (PMID: 33827525)
• 25 Miller LE, Chughtai B, Dornbier RA. et al. Surgical reintervention rate after prostatic urethral lift: systematic review and meta- analysis involving over 2,000 patients. J Urol 2020; 204: 1019-1026 DOI: 10.1097/JU.0000000000001132. (PMID: 32396049)
• 26 Netsch C, Abt D, Rieken M. et al. A (new) revolution in the treatment of benign prostatic hyperplasia? Aqua-ablation and prostate embolization. Urologe A 2020; 59: 1177-1186 DOI: 10.1007/s00120-020-01312-8. (PMID: 32886138)
• 27 Gilling P, Barber N, Bidair M. et al. WATER: a double-blind, randomized, controlled trial of aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018; 199: 1252-1261 DOI: 10.1016/j.juro.2017.12.065. (PMID: 29360529)
• 28 Pimentel MA, Yassaie O, Gilling P. Urodynamic outcomes after aquablation. Urology 2019; 126: 165-170 DOI: 10.1016/j.urology.2019.01.020. (PMID: 30721737)
• 29 Gilling PJ, Barber N, Bidair M. et al. Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology 2019; 125: 169-173 DOI: 10.1016/j.urology.2018.12.002. (PMID: 30552937)
• 30 Gilling P, Barber N, Bidair M. et al. Two-year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther 2019; 36: 1326-1336 DOI: 10.1007/s12325-019-00952-3. (PMID: 31028614)
• 31 Gilling P, Barber N, Bidair M. et al. Three-year outcomes after aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 2020; 27: 10072-10079
• 32 Gilling PJ, Barber N, Bidair M. et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol 2022; 29: 10960-10968
• 33 Gilfrich C, May M, Fahlenbrach C. et al. Surgical Reintervention Rates after Invasive Treatment for Lower Urinary Tract Symptoms due to Benign Prostatic Syndrome: A Comparative Study of More than 43,000 Patients with Long-Term Followup. J Urol 2021; 205: 855-863
• 34 Desai M, Bidair M, Bhojani N. et al. WATER II (80–150 mL) procedural outcomes. BJU Int 2019; 123: 106-112 DOI: 10.1111/bju.14360. (PMID: 29694702)
• 35 Yafi FA, Tallman CT, Seard ML. et al. Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). Int J Impot Res 2018; 30: 209-214
• 36 Zorn KC, Goldenberg SL, Paterson R. et al. Aquablation among novice users in Canada: a WATER II subpopulation analysis. Can Urol Assoc J 2019; 13: E113-E118
• 37 Desai M, Bidair M, Zorn KC. et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 mL): 6-month results from the WATER II trial. BJU Int 2019; 124: 321-328
• 38 Bhojani N, Bidair M, Zorn KC. et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 1-year results. Urology 2019; 129: 1-7 DOI: 10.1016/j.urology.2019.04.029. (PMID: 31059728)
• 39 Desai M, Bidair M, Bhojani N. et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 2-year results. Can J Urol 2020; 27: 10147-10153 (PMID: 32333733)
• 40 Zorn KC, Bidair M, Trainer A. et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass 2021; 3: 130-138 DOI: 10.1002/bco2.121. (PMID: 35474721)
• 41 Bhojani N, Bidair M, Kramolowsky E. et al. Aquablation Therapy in Large Prostates (80–150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. J Urol 2023; 210: 143-153 DOI: 10.1097/JU.0000000000003483. (PMID: 37115632)
• 42 Magistro G, Abt SD, Becher KF. et al. Surgical treatment options of lower urinary tract symptoms due to benign prostatic obstruction: The German S2e guideline 2023-part 3]. Urologie 2023; 62: 1177-1185 DOI: 10.1007/s00120-023-02200-7. (PMID: 37823934)
• 43 Martins Pisco J, Pereira J, Rio Tinto H. et al. How to perform prostatic arterial embolization. Tech Vasc Interv Radiol 2012; 15: 286-289
• 44 Mordasini L, Hechelhammer L, Diener PA. et al. Prostatic artery emboliza- tion in the treatment of localized prostate cancer: a bicentric prospective proof-of-concept study of 12 patients. J Vasc Interv Radiol 2018; 29: 589-597
• 45 McWilliams JP, Bilhim TA, Carnevale FC. et al. Society of interventional radiology multisociety consensus position statement on prostatic artery embolization for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia: from the society of interventional radiology, the cardiovascular and interventional radiological society of Europe, societe Francaise de radiologie, and the British society of interventional radiology: endorsed by the Asia pacific society of cardiovascular and interventional radiology, Canadian association for interventional radiology, Chinese college of interventionalists, interventional radiology society of Australasia, Japanese society of interventional radiology, and Korean society of interventional radiology. J Vasc Interv Radiol 2019; 30: 627-637
• 46 Abt D, Mullhaupt G, Mordasini L. et al. Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non- inferiority trial. BJU Int 2019; 124: 134-144 DOI: 10.1111/bju.14632. (PMID: 30499637)
• 47 Jung JHMK, Borofsky M, Young S. et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database 2020. Syst RevCD012867.
• 48 Zumstein V, Betschart P, Vetterlein MW. et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 2020; 5: 1091-1100 DOI: 10.1016/j.euf.2018.09.005. (PMID: 30292422)
• 49 Abt D, Hechelhammer L, Mullhaupt G. et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018; 361: k2338 DOI: 10.1136/bmj.k2338. (PMID: 29921613)
• 50 Carnevale FC, Iscaife A, Yoshinaga EM. et al. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) Due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic- controlled analysis. Cardiovasc Intervent Radiol 2016; 39: 44-52 DOI: 10.1007/s00270-015-1202-4. (PMID: 26506952)
• 51 Gao YA, Huang Y, Zhang R. et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate – a prospective, randomized, and controlled clinical trial. Radiology 2014; 270: 920-928 DOI: 10.1148/radiol.13122803. (PMID: 24475799)
• 52 Insausti I, Saez de Ocariz A, Galbete A. et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2020; 31: 882-890
• 53 Radwan A, Farouk A, Higazy A. et al. Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia. Prostate Int 2020; 8: 130-133 DOI: 10.1016/j.prnil.2020.04.001. (PMID: 33102395)
• 54 Zhu C, Lin W, Huang Z. et al. Prostate artery embolization and transurethral resection of prostate for benign prostatic hyperplasia: a prospective randomized controlled trial. Chin J Interv Imaging Ther 2018; 15: 134-138
• 55 Pisco JM, Bilhim T, Costa NV. et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol 2020; 77: 354-362 DOI: 10.1016/j.eururo.2019.11.010. (PMID: 31831295)
• 56 Pisco JM, Bilhim T, Pinheiro LC. et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 2016; 27: 1115-1122
• 57 Abt D, Mullhaupt G, Hechelhammer L. et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol 2021; 80: 34-42 DOI: 10.1016/j.eururo.2021.02.008. (PMID: 33612376)
• 58 Ray AF, Powell J, Speakman MJ. et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK- ROPE study). BJU Int 2018; 122: 270-282
• 59 Zumstein V, Binder J, Gusewell S. et al. Radiation exposure during prostatic artery embolisation: a systematic review and calculation of associated risks. Eur Urol Focus 2021; 7: 608-611
• 60 Bhatia S, Sinha VK, Kava BR. et al. Efficacy of prostatic artery embolization for catheter- dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol 2018; 29: 78-84e1
• 61 Dixon CM, Rijo Cedano E, Mynderse LA. et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum(®) system: evaluation of acute ablative capabilities in the human prostate. RRU 2015; 7: 13-18
• 62 Mynderse LA, Hanson D, Robb RA. et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 2015; 86: 122-127
• 63 McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic Hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171-179 DOI: 10.1016/j.urology.2018.12.041. (PMID: 30677455)
• 64 Dixon CM, Cedano ER, Pacik D. et al. Two- year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. RRU 2016; 8: 207-216 DOI: 10.2147/RRU.S119596. (PMID: 27921028)
• 65 Johnston MJ, Noureldin M, Abdelmotagly Y. et al. Rezum water vapour therapy: promising early outcomes from the first UK series. BJU Int 2020; 126: 557-558
• 66 McConnell JD, Roehrborn CG, Bautista O. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398 DOI: 10.1056/NEJMoa030656. (PMID: 14681504)
• 67 McVary KT, Rogers T, Mahon J. et al. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?. J Sex Med 2018; 15: 1728-1738 DOI: 10.1016/j.jsxm.2018.10.006. (PMID: 30446471)
• 68 Gupta N, Rogers T, Holland B. et al. Three-year treatment outcomes of water vapor thermal therapy compared to do- xazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol 2018; 200: 405-413
• 69 Miller LE, Te AE, Bhattacharyya SK. et al. A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia. Expert Rev Med Devices 2018; 17: 365-369 DOI: 10.1080/17434440.2020.1742699. (PMID: 32189535)
• 70 McVary KT, Holland B, Beahrs JR. Water vapor thermal therapy to alleviate catheter- dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2020; 23: 303-308 DOI: 10.1038/s41391-019-0187-5. (PMID: 31740738)
• 71 Bole R, Gopalakrishna A, Kuang R. et al. Comparative postoperative outcomes of Rezu ̄ m prostate ablation in patients with large versus small glands. J Endourol 2020; 34: 778-781
• 72 McVary KT, Gange SN, Gittelman MC. et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195: 1529-1538 DOI: 10.1016/j.juro.2015.10.181. (PMID: 26614889)
• 73 Garden EB, Shukla D, Ravivarapu KT. et al. Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes. World J Urol 2021; 39: 3041-3048
• 74 Dixon C, Cedano ER, Pacik D. et al. Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urology 2015; 86: 1042-1047 DOI: 10.1016/j.urology.2015.05.046. (PMID: 26216644)
• 75 Darson MF, Alexander EE, Schiffman ZJ. et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezu ̄ m system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. RRU 2017; 9: 159-168
• 76 Kang TW, Jung JH, Gwang EC. et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2020; 3: CD013251
• 77 Lerner LB, McVary KT, Barry MJ. et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. J Urol 2021; 206: 818-826 DOI: 10.1097/JU.0000000000002184. (PMID: 34384236)
• 78 Singh A, Faris S, Agarwal P. et al. Association between Industry Payments and Published Position on Use of Devices for the Treatment of Lower Urinary Tract Symptoms. Urology 2022; 159: 87-92
• 79 Durant AM, Moore J, Voleti S. et al. Salvage versus primary holmium laser enucleation of the prostate: trends, outcomes and safety analysis. World J Urol 2022; 40: 2305-2312 DOI: 10.1007/s00345-022-04098-w. (PMID: 35867143)
• 80 Gross AJ, Lipp MJ, Baumbach R. et al. Rectal perforation after aquablation of the prostate: lessons learned the hard way. World J Urol 2021; 39: 3441-3446 DOI: 10.1007/s00345-021-03660-2. (PMID: 33770242)
• 81 Kaplan-Marans E, Martinez M, Wood A. et al. Aquablation, Prostatic Urethral Lift, and Transurethral Water Vapor Therapy: A Comparison of Device-Related Adverse Events in a National Registry. J Endourol 2022; 36: 231-235 DOI: 10.1089/end.2021.0455. (PMID: 34314240)
• 82 Weiss JK, Santucci NM, Sajadi KP. et al. Post-Surgical Complications After Bladder Outlet Reducing Surgery: An Analysis of The FDA Manufacturer and User Facility Device Experience (MAUDE) Database. Urology 2021; 156: 211-215 DOI: 10.1016/j.urology.2021.04.030. (PMID: 33971189)
• 83 Porto JG, Arbelaez MCS, Blachman-Braun R. et al. Complications associated with minimally invasive surgical therapies (MIST) for surgical management of benign prostatic hyperplasia: a Manufacturer and User Facility Device Experience (MAUDE) database review. World J Urol 2023; 41: 1975-1982